Literature DB >> 10603409

Isolates of Chlamydia trachomatis that occupy nonfusogenic inclusions lack IncA, a protein localized to the inclusion membrane.

R J Suchland1, D D Rockey, J P Bannantine, W E Stamm.   

Abstract

The chlamydiae are obligate intracellular pathogens that occupy a nonacidified vacuole, termed an inclusion, throughout their developmenal cycle. When an epithelial cell is infected with multiple Chlamydia trachomatis elementary bodies, they are internalized by endocytosis into individual phagosomal vacuoles that eventually fuse to form a single inclusion. In the course of large-scale serotyping studies in which fluorescent antibody staining of infected cells was used, a minority of strains that had an alternate inclusion morphology were identified. These variants formed multiple nonfusogenic inclusions in infected cells, with the number of independent inclusions per cell varying directly with the multiplicity of infection. Overall the nonfusogenic phenotype was found in 1.5% (176 of 11,440) of independent isolates. Nonfusing variants were seen in C. trachomatis serovars B, D, D-, E, F, G, H, Ia, J, and K. The nonfusing phenotype persisted through repeated serial passage, and the phenotype was consistent in four mammalian host cell lines. Fluorescence microscopy and immunoblotting with antisera directed at proteins in the C. trachomatis inclusion membrane revealed that one such protein, IncA, was not detected in the inclusion membrane in each tested nonfusogenic strain. The distributions of other chlamydial proteins, including one additional Inc protein, were similar in wild-type and variant strains. The incA coding and upstream regions were amplified and sequenced from the prototype serovar D and two nonfusing serovar D((s)) strains. Three nucleotide changes were discovered in the D((s)) incA gene, leading to two amino acid changes within the predicted D((s)) IncA sequence. These studies demonstrate a subgroup of variant C. trachomatis isolates that form nonfusing inclusions; the variant phenotype is associated with the absence of detectable IncA and with an altered incA sequence that modifies the characteristic hydrophobic domain of the IncA protein.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10603409      PMCID: PMC97142          DOI: 10.1128/IAI.68.1.360-367.2000

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  28 in total

Review 1.  Biology of chlamydiae.

Authors:  P B Wyrick; S J Richmond
Journal:  J Am Vet Med Assoc       Date:  1989-12-01       Impact factor: 1.936

2.  A secondary structure motif predictive of protein localization to the chlamydial inclusion membrane.

Authors:  J P Bannantine; R S Griffiths; W Viratyosin; W J Brown; D D Rockey
Journal:  Cell Microbiol       Date:  2000-02       Impact factor: 3.715

3.  Redundant in vivo proteolytic activities of Escherichia coli Lon and the ClpYQ (HslUV) protease.

Authors:  W F Wu; Y Zhou; S Gottesman
Journal:  J Bacteriol       Date:  1999-06       Impact factor: 3.490

4.  Identification and characterization of a Chlamydia trachomatis early operon encoding four novel inclusion membrane proteins.

Authors:  M A Scidmore-Carlson; E I Shaw; C A Dooley; E R Fischer; T Hackstadt
Journal:  Mol Microbiol       Date:  1999-08       Impact factor: 3.501

5.  Fusion of inclusions following superinfection of HeLa cells by two serovars of Chlamydia trachomatis.

Authors:  J C Ridderhof; R C Barnes
Journal:  Infect Immun       Date:  1989-10       Impact factor: 3.441

6.  Immunotyping of Chlamydia trachomatis with monoclonal antibodies.

Authors:  S P Wang; C C Kuo; R C Barnes; R S Stephens; J T Grayston
Journal:  J Infect Dis       Date:  1985-10       Impact factor: 5.226

7.  Biotyping of Chlamydia psittaci based on inclusion morphology and response to diethylaminoethyl-dextran and cycloheximide.

Authors:  P Spears; J Storz
Journal:  Infect Immun       Date:  1979-04       Impact factor: 3.441

8.  Simplified microtiter cell culture method for rapid immunotyping of Chlamydia trachomatis.

Authors:  R J Suchland; W E Stamm
Journal:  J Clin Microbiol       Date:  1991-07       Impact factor: 5.948

9.  Rapid immunotyping of Chlamydia trachomatis with monoclonal antibodies in a solid-phase enzyme immunoassay.

Authors:  R C Barnes; S P Wang; C C Kuo; W E Stamm
Journal:  J Clin Microbiol       Date:  1985-10       Impact factor: 5.948

10.  Ultrastructural study of endocytosis of Chlamydia trachomatis by McCoy cells.

Authors:  R L Hodinka; C H Davis; J Choong; P B Wyrick
Journal:  Infect Immun       Date:  1988-06       Impact factor: 3.441

View more
  64 in total

1.  Normal IncA expression and fusogenicity of inclusions in Chlamydia trachomatis isolates with the incA I47T mutation.

Authors:  Y Pannekoek; A van der Ende; P P Eijk; J van Marle; M A de Witte; J M Ossewaarde; A J van den Brule; S A Morré; J Dankert
Journal:  Infect Immun       Date:  2001-07       Impact factor: 3.441

Review 2.  Genome sequencing and our understanding of chlamydiae.

Authors:  D D Rockey; J Lenart; R S Stephens
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

3.  Expression and localization of type III secretion-related proteins of Chlamydia pneumoniae.

Authors:  R Lugert; M Kuhns; T Polch; U Gross
Journal:  Med Microbiol Immunol       Date:  2003-10-31       Impact factor: 3.402

4.  Resistance to a novel antichlamydial compound is mediated through mutations in Chlamydia trachomatis secY.

Authors:  Kelsi M Sandoz; Steven G Eriksen; Brendan M Jeffrey; Robert J Suchland; Timothy E Putman; Dennis E Hruby; Robert Jordan; Daniel D Rockey
Journal:  Antimicrob Agents Chemother       Date:  2012-05-29       Impact factor: 5.191

Review 5.  Genetic variation in Chlamydia trachomatis and their hosts: impact on disease severity and tissue tropism.

Authors:  Hossam Abdelsamed; Jan Peters; Gerald I Byrne
Journal:  Future Microbiol       Date:  2013-09       Impact factor: 3.165

6.  A small-molecule inhibitor of type III secretion inhibits different stages of the infectious cycle of Chlamydia trachomatis.

Authors:  Sandra Muschiol; Leslie Bailey; Asa Gylfe; Charlotta Sundin; Kjell Hultenby; Sven Bergström; Mikael Elofsson; Hans Wolf-Watz; Staffan Normark; Birgitta Henriques-Normark
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-14       Impact factor: 11.205

7.  Development of secondary inclusions in cells infected by Chlamydia trachomatis.

Authors:  Robert J Suchland; Daniel D Rockey; Sara K Weeks; Damir T Alzhanov; Walter E Stamm
Journal:  Infect Immun       Date:  2005-07       Impact factor: 3.441

8.  Treatment of Chlamydia trachomatis with a small molecule inhibitor of the Yersinia type III secretion system disrupts progression of the chlamydial developmental cycle.

Authors:  K Wolf; H J Betts; B Chellas-Géry; S Hower; C N Linton; K A Fields
Journal:  Mol Microbiol       Date:  2006-09       Impact factor: 3.501

9.  Identification of concomitant infection with Chlamydia trachomatis IncA-negative mutant and wild-type strains by genomic, transcriptional, and biological characterizations.

Authors:  Robert J Suchland; Brendan M Jeffrey; Minsheng Xia; Ajay Bhatia; Hencelyn G Chu; Daniel D Rockey; Walter E Stamm
Journal:  Infect Immun       Date:  2008-10-13       Impact factor: 3.441

10.  Conservation of extrusion as an exit mechanism for Chlamydia.

Authors:  Meghan Zuck; Ashley Sherrid; Robert Suchland; Tisha Ellis; Kevin Hybiske
Journal:  Pathog Dis       Date:  2016-09-11       Impact factor: 3.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.